Soltau Jens, Drevs Joachim
Tumor Biology Center, Department of Medical Oncology, Breisacher Strasse 117, 79106 Freiburg, Germany.
IDrugs. 2004 Apr;7(4):380-7.
AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.
阿斯利康正在研发ZD-6126,它是血管靶向和微管蛋白结合剂ANG-400系列中的一种,已获Angiogene制药有限公司授权,用于癌症的潜在治疗。